U.S. Food and Drug Administration today approved the second late-stage melanoma drug this year, adding the drug to the treatment arsenal for patients with one of the deadliest forms of skin cancer. The drug, known as Zelboraf, could offer hope for patients with metastatic melanoma that cannot be removed with surgery, experts said. Zelboraf, which was reviewed under the FDA's priority review program, received advanced approval after…